Akorn Ratio court
Quel est le Ratio court de Akorn?
Le Ratio court de Akorn, Inc. est 0.49
Quelle est la définition de Ratio court?
Le ratio court des actions vendues est le nombre d'actions vendues à découvert divisé par le volume quotidien moyen.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Ratio court des entreprises dans Health Care secteur sur OTC par rapport à Akorn
Que fait Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Entreprises avec ratio court similaire à Akorn
- Acorn International Inc a Ratio court de 0.48
- Calyx Ventures a Ratio court de 0.48
- Condor Hospitality Trust Inc a Ratio court de 0.48
- Vivaldi Opportunities Fund a Ratio court de 0.48
- HTG Molecular Diagnostics Inc a Ratio court de 0.48
- Otelco Inc a Ratio court de 0.48
- Akorn a Ratio court de 0.49
- Axovant Gene Therapies a Ratio court de 0.50
- Fieldex Exploration a Ratio court de 0.50
- CMC Metals a Ratio court de 0.50
- Peeks Social a Ratio court de 0.50
- Xortx Therapeutics Inc a Ratio court de 0.50
- Visionary Gold a Ratio court de 0.50